ArticlePharmacoEconomics2024

Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.

Mirre Scholte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.